Company profile
Fluent Corp.
OTC: CNTMF · Healthcare · Drug Manufacturers - Specialty & Generic
#363 of 1,418 Healthcare companies by revenue30th-percentile growth
EA Score
45DFH 42DQ —GM 49SS 52
v0.1 · 45/100 weight · provisional
↑ workforce scale, growth stability · ↓ Piotroski F, balance-sheet leverage
Methodology →Revenue TTM
$68.2M
Rev growth YoY (TTM)
-34.7%
Net income (FY)
-$72.5M
Employees
826
as of 2026-09-20
Market cap
$10.5M
as of 2026-09-20
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$86.7M$86.7M2025
Net income-$72.5M-$72.5M2025
Operating income-$15.2M-$15.2M2025
Total assets$148.6M$148.6M2025
Liabilities$229.5M$229.5M2025
Equity-$81.0M-$81.0M2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Fluent Corp.’s revenue?
Fluent Corp. booked $86.7M in FY2025 revenue, contracting 16% year over year — slower than 70% of Healthcare companies we track, at a -83.6% net margin.
Peers · Healthcare
CeriBell, Inc.48DBiodesix, Inc.57CCytokinetics, Incorporated59CHarvard Bioscience, Inc.58C4Front Ventures Corp.——Standard BioTools Inc.61CNeighbors
Miami-Dade →Key facts
CEOMatthew Mundy
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersMiami, FL
ExchangeOTC: CNTMF
Employees826
IPO date2021-01-08
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.